Trial Profile

Open label study of ONTAK (denileukin diftitox, DAB389IL-2) to estimate response in cutaneous T-cell lymphoma (CTCL) according to CD25 status.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denileukin diftitox (Primary)
Indications Cutaneous T-cell lymphoma
Focus Therapeutic Use
Sponsors Ligand Pharmaceuticals

Most Recent Events

09 Sep 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
22 May 2007 Status changed from in progress
11 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com